



INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
		Filing Date 06/06/1999		Group Art Unit 1616	
UNITED STATES PATENT DOCUMENTS					
Examiner Initial	Document No.	Date	Name		Class
DWP	10/110865	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith)		
	10/110830	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith)		
	10/110812	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith)		
	10/110862	10/18/00	*1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith)		
	10/111059	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith)		
	2002/0119972	8/29/02	Leftheris et al		
	2003/0120094	6/26/03	Makriyannis et al		
	3041343	6/26/62	Jucker et al		
	3573327	3/30/71	Miyano		
	3656906	4/18/72	Bullock		
	3886184	5/27/75	Matsumoto et al		
	3897306	7/29/75	Vidic		
	3915996	10/28/75	Wright		
	3928598	12/23/75	Archer		
	3944673	3/16/76	Archer		
	3953603	4/27/76	Archer		
Amf	4036857	7/19/77	Razdan et al		




INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
			Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
			Filing Date 06/06/1999		Group Art Unit 1616	
<i>[initials]</i>	4054582	10/18/77	Blanchard et al			
	4087545	5/2/78	Archer et al			
	4087546	5/2/78	Archer et al			
	4087547	5/2/78	Archer et al			
	4088777	5/9/78	Archer et al			
	4102902	7/25/78	Archer et al			
	4152450	5/1/79	Day et al			
	4171315	10/16/79	Ryan et al			
	4176233	11/27/79	Archer et al			
	4179517	12/18/79	Mechoulam			
	4188495	2/12/80	Althuis et al			
	4208351	6/17/80	Archer et al			
	4278603	7/14/81	Thakkar et al			
	4282248	8/4/81	Mechoulam et al			
	4382943	5/10/83	Winter et al			
	4395560	7/26/83	Ryan			
	4550214	10/29/85	Mehta			
	4758597	7/19/88	Martin et al			
	4876276	10/24/89	Mechoulam			
	4885295	12/5/89	Bell et al			
	5053548	10/1/91	Tanaka et al			
	5068234	11/26/91	D'Ambra et al			
	5147876	9/15/92	Mizuchi et al			
	5223510	6/29/93	Gubin et al			
	5284867	2/8/94	Kloog			
	5324737	6/28/94	D'Ambra et al			
	5434295	7/18/95	Mechoulam et al			
	5440052	8/8/95	Makriyannis et al			
	5462960	10/31/95	Barth et al			
	5489580	2/6/96	Makriyannis et al			
	5521215	5/28/96	Mechoulam			
	5532237	7/2/96	Gallant et al			
	5538993	7/23/96	Mechoulam			
	5605906	2/25/97	Lau			
	5607933	3/4/97	D'Ambra et al			
	5624941	4/29/97	Barth et al			
<i>[initials]</i>	5635530	6/3/97	Mechoulam			





INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
			Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
			Filing Date 06/06/1999		Group Art Unit 1616	Docket No. UCONAP/141/US
<i>AWP</i>	5747524	5/5/98	Cullinan et al			
	5744459	4/28/98	Makriyannis et al			
	5817651	10/6/98	D'Ambra et al			
	5872148	2/16/99	Makriyannis et al			
	5925768	7/20/99	Barth et al			
	5932610	8/3/99	Shohami et al			
	5948777	9/7/99	Bender et al			
	6013648	1/11/00	Rinaldi et al (appears equivalent to FR2735774)			
	6028084	2/22/00	Barth et al			
	6096740	9/1/00	Mechoulam			
	6127399	10/3/00	Yuan			
	6166066	12/26/00	Makriyannis et al			
<i>AWP</i>	6284788	10/4/01	Mittendorf et al (appears equivalent to EP860168)			
FOREIGN PATENT DOCUMENTS						
Examiner Initial	Document No.	Date	Country	Name		Translation
<i>AWP</i>	EP0276732	8/3/88	EP	Hoffman La Roche		
	EP0471609	6/29/93	EP	Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510)		
	EP0737671	10/16/96	EP	*1* Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)		
<i>AWP</i>	EP0860168	9/4/01	EP	Mittendorf et al, in German, front page only (including English bibliography, appears equivalent to US6284788)		





INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
			Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
			Filing Date 06/06/1999		Group Art Unit 1616	Docket No. UCONAP/141/US
DWP	FR2240003	5/27/75	FR	Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184)		
	FR2735774	1/11/00	FR	Barth et al, in French (including English bibliography and abstract, appears equivalent to US6013648)		
	GB2027021A	2/13/80	GB	Mechoulam et al, in English (appears equivalent to US4282248)		
	JP2304080	12/17/90	JP	Nakayama Hajime et al, in Japanese (including English bibliography and abstract)		
	JP57098228	6/18/82	JP	Noda et al, in Japanese (including English bibliography and abstract)		
	WO 00/32200	6/8/00		*1* Makriyannis et al, in English		
	WO 01/28329	4/26/01		Makriyannis et al, in English		
	WO 01/28497	4/26/01		Makriyannis et al, in English		
	WO 01/28498	4/26/01		Makriyannis et al, in English		
	WO 01/28557	4/26/01		Makriyannis et al, in English		
	WO 01/29007	4/26/01		Makriyannis et al, in English		
	WO 01/32169	5/10/01		Fride et al, in English		
	WO 01/58869	8/16/01		Pandit et al, in English, first page only (including bibliography and abstract, appears equivalent to US2002/0119972)		
	WO 97/00860	1/9/97		Rinaldi et al, in French (including English bibliography and abstract, appears equivalent to US6013648)		
	WV	WO 99/57107	11/11/99		Makriyannis et al, in English	





INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents			
		Filing Date 06/06/1999		Group Art Unit 1616	Docket No. UCONAP/141/US
	WO 99/64389	12/16/99		*1* Makriyannis et al, in English	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Examiner Initial					
	Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768				
	*** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977)				
	Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacol, (1997) 132, 104-106. (abstract only)				
	Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36				
	Belgaonkar et al; "synthesis of isocoumarins"; Indian J. Chem; vol. 13; no. 4; 336-338; 1975 (abstract only)				
	Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90				
	Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; "Synthesis of 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines"; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 (abstract only)				
	Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered 9 – tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. (abstract only)				
	*** Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876.				
	Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990)				

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742		Inventor Alexandros Makriyannis et al		
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents				
		Filing Date 06/06/1999		Group Art Unit 1616		Docket No. UCONAP/141/US
Buckley NE, McCoy KI, Mpzey E et al, "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor"; Eur. J Pharmacol (2000) 396:141-149.						
Burstein et al; "detection of cannabinoid receptors . . ."; Biochem. Biophys. Res. Commun.; vol. 176(1); 492-497; 1991 (abstract only)						
Busch-Peterson et al; "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs"; J. Med. Chem.; 39; 3790-3796; (1996)						
Calignano A, La Rana G, Diuffrida A, Piomelli D; "Control of pain initiation by endogenous cannabinoids"; Nature (1998) 394:277-291. (abstract only)						
Campbell FA et al; "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review"; BMJ. 2001 Jul 7;323(7303):13-6						
Charalambous A. et al; "5'-azido 8-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor"; J. Med. Chem., 35, 3076 - 3079 (1992)						
Charalambous A. et al; "Pharmacological evaluation of halogenated . . ."; Pharmacol. Biochem. Behav.; vol. 40; no. 3; 509-512; 1991						
Cheng et al; "Relationship Between the Inhibition Constant (Ki) and the concentration of Inhibitor which causes 50% Inhibition (IC50) of an Enzymatic Reaction"; Biochem. Pharmacol., 22, 3099-3102, (1973) (abstract only)						
Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. (abstract only)						
Compton et al; "Synthesis and pharmacological evaluation of ether and related analogues of delta8-, delta9- and delta9,11-tetrahydrocannabinol"; J. Med. Chem; vol. 34; no. 11; 3310-3316; 1991						
Consroe P, Musty R, Rein J, Tillery W, Pertwee R; "The perceived effects of smoked cannabis on patients with multiple sclerosis"; Eur. Neurol. (1997) 38-44-48. (abstract only)						
Coxon et al; "Derivatives of nopinone"; Aust. J. Chem.; 23; 1069-1071; (1970) (abstract only)						
Crawley et al; "Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents"; Pharmacology Biochemistry and Behavior; vol. 46; 967-972; 1993						
D'Ambra et al; "C-attached aminoalkylindoles: potent cannabinoid mimetics"; Bioorg. & Med. Chem. Lett., 1996, 6(1), 17-22						



INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> OFFICE </div>		DePetrocellis L, Melck D, Palmisano A. et al; "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation"; Proc. Natl. Acad. Sci. USA (July 1998) 95:8375-8380.		
		Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). (abstract only)		
		Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528.		
		*** Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981).		
		Dominiani et al; "Synthesis of 5-(tert-Alkyl)resorcinols"; J. Org. Chem. 42(2); 344-346; (1977)		
		Drake et al, "classical/nonclassical hybrid cannabinoids"; J. Med. Chem.; vol. 41(19); 3596-3608 (1998)		
		Edery et al; "Activity of novel aminocannabinoids in baboons"; J. Med. Chem.; 27; 1370-1373 (1984)		
		Eissenstat et al; "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics"; J. Med. Chem. 1995, Vol. 38, No. 16, pp. 3094-3105; XP 000651090		
		Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl- Δ^9 -Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941		
		Fahrenholtz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111824		
	Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 (abstract only)			
	Galiegue S et al. ; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. (abstract only)			
	Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocannabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
JCI17 MARK OFFICE		Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992		
		*** Green K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophibalmol. (1998) feb 433-1437.		
		Hampson, A.J., Grimaldi M. Axpirod J. Wink D; "Cannabidiol and (-) 9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273.		
		Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) (abstract only)		
		*** Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391.		
		Herzberg U, Eliav E, Bennett GJ, Kopin IJ; "The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain"; Neurosci. Letts. (1997) 221; 157-160.		
		1 Horrevoets A.J.G et al; "Inactivation of reconstituted escherichia coli outer membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 255-261; 1991		
		Howlett et al; "Azido and isothicyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction"; Journal of Neurochemistry; vol. 74(5) (2000) 2174-2181; XP001097394		
		Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990		
		Huffman et al; "3-(1',1'-dimethylbutyl)--deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999)		
	Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995)			
	Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997)			
	Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic & Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230			




INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742		Inventor Alexandros Makriyannis et al		
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents				
		Filing Date 06/06/1999		Group Art Unit 1616		Docket No. UCONAP/141/US
PACIFIC OFFICE		Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086				
		*** Joy JE, Wagtson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999).				
		Kaminski NE; "Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors"; J Neuroimmunol. 1998 Mar 15;83(1-2):124-32				
		Khanolkar et al; "Molecular probes for the cannabinoid receptors"; Chemistry and Physics of Lipids; 108; 37-52; (2000)				
		Klein T.W. et al, "The cannabinoid system and cytokine network"; Proc Soc Exp Biol Med. 2000 Oct; 225(1):1-8; (abstract only)				
		Klein TW et al, "Cannabinoid receptors and immunity"; Immunol Today; 1998 Aug; 19(8):373-81				
		Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; Anesthesia, 2001, 56: 1059-1068 (abstract only)				
		Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; J. Med. Chem.; vol. 42(4); 769-776; (1999)				
		Lavalle et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; J. Org. Chem.; vol. 51(8); 1362-1365; (1986)				
		Loev, B., Bender, P. E., Dowalo, F., Macko, E., and Fowler, P.; "Cannabinoids. Structure-Activity Studies Related to 1,2-Dimethylheptyl Derivatives"; J. Med. Chem.; vol. 16(11); 1200-1206; 1973				
		Lozinskii, M.O., Bodnar, V.N., Konovalikhin, S.V., D'yachenko, O.A., Atovmyan, L.O.; "Unusual transformations of arylhydrazonoyl chlorides of oxalic acid ethyl ester"; Izvestiya Akademii Nauk SSSr, Seriya Khimicheskaya; 11; 2635-2637; 1990 (abstract only)				
		Ludt, R.E. et al; "A comparison of the synthetic utility of n-butyllithium and lithium diisopropylamide in the metalations of N,N-dialkylouamides"; J. Org. Chem.; 38(9); 1668-1674 (1973)				
		*** Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255				
		*** Markwell et al; Anal. Biochem.; 87:206 (1978)				
		Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991				





INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al
		Title Inhibitors of the Anandamide Transporter as Analgesic Agents	
		Filing Date 06/06/1999	Group Art Unit 1616
		Docket No. UCONAP/141/US	
		Martyn CN, Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579.	
		Matsumoto et al; "Cannabinoids 1.1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825	
		*** Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990); Z40:1-4.	
		Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; Biochimica et Biophysica Acta; vol 1281(2); 1996; XP00211823	
		Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980)	
		Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) (abstract only)	
		*** Mechoulam et al; Tetrahedron Asymmetry; 1: 315-318; (1990)	
		*** Mechoulam, "Cannabinoids as therapeutic agents"; CRC press, 1986	
		Meltzer et al; "An improved synthesis of cannabinol and cannabiorcol"; Synthesis; 1981:985 (1981)	
		*** Melvin et al; drug design and discovery; 13; 155-166 (1995)	
		Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993)	
		Merck Index; 11th edition; "Tetrahydrocannabinols" compound no. 9142; 1989	
		*** Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).	
		*** Morris, S.; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427	
		*** Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27.	
		*** Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents	
	Filing Date 06/06/1999	Group Art Unit 1616
	Docket No. UCONAP/141/US	
	*** Nahas G, <i>Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ</i>	
	Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) (abstract only)	
	Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985	
	*** Palmer et al; <i>current pharmaceutical design; 6; 1381-1397; (2000)</i>	
	Papahatjis et al; "A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules"; Chemistry Letters, 192; (2001)	
	Papahatjis et al; "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta8-tetrahydrocannabinols"; J. Med. Chem.; 41(7); 1195-1200; (1998)	
	Pertwee et al; "AM630, a competitive cannabinoid receptor agonist"; Life Sci. 1995, 56(23/24), 1949-1955; XP 000653566	
	Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044	
	Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; Pharmacol. Ther., vol. 74(2); pp129-180; (1997); XP002226467	
	Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; ".alpha.,.beta.-unsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethynyl)tellurolates with C-ethoxycarbonyl-N-Phenylnitrilimine"; Zhurnal Organicheskoi Khimii; 29(7); 1372-1378; (1993) (abstract only)	
	*** Pinnegan-Ling D, Musty R.; <i>Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53.</i>	
	Pitt et al; "The synthesis of Deuterium, carbon-14 and carrier free tritium labelled cannabinoids"; Journal of Labelled Compounds; vol. 11(4); 551-575; 1975; XP002123229	
	Razdan et al; "Drugs delivered from cannabinoids. 6. .Synthesis of cyclic analogues of dimethylheptylpyran"; J. Med. Chem.; vol. 19(5); 719-721; 1976 (abstract only)	
	Reggio et al; "Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach"; J. Med. Chem. United States; vol. 36(12); 1761-1771; 1993	



INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
C117 MARK OFFICE	ANP	Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcyclase"; J. Med. Chem. 1997, 40(20); 3228-3233	
		*** Rice AS. <i>Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414</i>	
		Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of spinal cannabinoids"; Eur. J. Pharmacol. (1998) 346:145-153.	
		Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors"; Pain (1998) 75:111-119.	
		Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995)	
		Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994)	
		Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989	
		Santus, Maria; "Studies on thioamides and their derivatives. IX. Synthesis of the derivatives of 1,2,4,5-tetrazine"; Acta Polonae Pharmaceutica; 50(2-3); 183-188; 1993 (abstract only)	
		Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87	
		*** Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., <i>Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a.</i>	
	Shawali, A.S., Albar, H.A.; "Kinetics and mechanism of dehydrochlorination of N-aryl-C-ethoxycarbonyl formohydrazidoyl chlorides"; Canadian Journal Of Chemistry; 64(5); 871-875; 1986 (abstract only)		
	*** Shen M. Thayer SA: <i>Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.</i>		
ANP	Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771		
	Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands"; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918		
	*** Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181.		
	*** Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172.		
	Tius et al; "Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity"; Tetrahedron; 50 (9); 2671-2680; (1994) (abstract only)		
	*** Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534		
	*** Wagner JA, Varga K, Jarai Z, Kunos G; 'Mesenteric vasodilation mediated by endothelial anandamide receptors'; Hypertension (1999) 33:429-434.		
	Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; Synlett 1992, 207-210		
	Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; J. Pharmacol. Exp. Ther. 1998, 285(3), 995-1004; XP-001097982		
	Wilson et al; "9-nor-delta8-tetrahydrocannabinol, a cannabinoid of metabolic interests"; J. Med. Chem.; 17(4); 475-476; (1974)		
	Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; J. Med. Chem.; 18(7); 700-703; (1975)		
	Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; J. Med. Chem.; 19(9); 1165-1167; (1976)		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter as Analgesic Agents		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
<i>Amf</i>	Yamada et al; "(Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974		
<i>Amf</i>	Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol: a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994)		
<i>Amf</i>	Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994)		
Examiner <i>Alton Pryor</i>	Date Considered <i>4/11/05</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			


INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter			
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US	



UNITED STATES PATENT DOCUMENTS

Examiner Initial - date	Document No.	Date	Name	Class
[Signature]	09/698,071	10/30/00	Fride et al, (copy not included, this is the parent application for US Publication No. 2002/0173528, enclosed herewith)	
	2002/0173528	11/21/02	Fride et al	
	3838131	9/24/74	Gauthier	
	3946029	3/23/76	Descamps et al	
	5631297	5/20/97	*1* Pate et al	
	5939429	8/17/99	Kunos et al	

FOREIGN PATENT DOCUMENTS


Examiner Initial - date	Document No.	Date	Country	Name	Translation
[Signature]	EP0444451	9/4/91	EP	Sterling Drug (English bibliography, abstract and cover page, appears equivalent to US5068234 which was previously cited)	
	EP0576357	12/29/93	EP	Barth et al (including English bibliography and abstract)	no
	EP0737671	10/16/96	EP	Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)	
	IL1995-113228	9/22/99	IL	*1* R. Mechoulam et al (abstract only)	
	WO 02/058636	8/1/02		Makriyannis et al	English
	WO 02/060447	8/8/02		Makriyannis et al	English
	WO 99/57106	11/11/99		Makriyannis et al	English
	WO 97/21682	6/19/97		Barth et al (including bibliography, appears equivalent to US5925768)	no
	WO 94/12466	06/94		*1* Yissum Research Development Co.	English

INFORMATION DISCLOSURE CITATION IN AN OIP E APPLICATION 		Application No. 09/328,742		Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter			
		Filing Date 06/06/1999		Group Art Unit 1616	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Examiner Initial - date					
JWP		*2* Brothie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876. (abstract only)			
		Compton D.R. et al; "Pharmacological Profile Of A Series Of Bicyclic Cannabinoid Analogs: Classification as Cannabimimetic Agents"; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992. (abstract only)			
		2 Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981). (abstract only)			
		2 Green K.; "Marijuana smoking vs. cannabinoids for glaucoma therapy."; Arch. Ophthalmol. (1998) Nov. 116(11); 1433-1437. (abstract only)			
		Griffin, G., Wray, E. J., Tao, Q., McAllister, S. D., Rorrer, W. K., Aung, M., Martin, B. R., Abood, M. E.; "Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system"; European Journal of Pharmacology; (1999); vol. 377; 117-125.			
		1 Hanus et al; "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor"; Journal of medicinal Chemistry; 36(20); 3032-3034; 1993			
		Jbilo, O., Derocq, J., Segui, M., Le Fur, G., Casellas, P.; "Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60"; FEBS LETTERS; (1999); vol. 448; no. 21848; 273-277			
		2 Joy JE, Watson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999). (abstract only)			
		1 Lang, W. et al; "Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase"; J. Med. Chem.; vol. 42(5); 896-902; (1999)			
AW		*1* Lang, W., Qin, C., Hill, W.A., Lin, S., Khanolkar, A.D., Makriyannis, A.; High-Performance Liquid Chromatographic Determination Of Anandamide Amidase Activity in Rat Brain Microsomes; Anal. Biochem; (1996), 238, 40-45 (abstract only)			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
		*2* Maurer-Morelli V, Dittrich A, Hofmann A.; "Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial."; Eur. Arch. Psychiat. Clin. Neurosci. (1990), 240:1-4. (abstract only)		
		1 Mechoulam et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667.		
		1 Mechoulam et al; "Towards Cannabinoid drugs - Revisited"; Progress in Medicinal Chemistry; 35; 199-243; 7/3/1998		
		Meschler, J. P., Kraichely, D. M., Wilken, G. H., Howlett, A. C.; "Inverse Agonist Properties of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCL (SR141716A) and 1-(2-Chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic Acid Phenylamide (CP-272871) for the CB1 Cannabinoid Receptor"; Biochemical Pharmacology; (2000); vol. 60; no. 9; 1315-1322.		
		Melvin et al; "Structure-Activity Relationships Defining the ACD-Tricyclic Cannabinoids Cannabinoid Receptor Binding and Analgesic Activity"; Drug Design and Discovery; 13(2); 155-166 (1995). (abstract only)		
		2 Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. (abstract only)		
		2 Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM.; "Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol." Am. J. Psychiat.; (1999); 156(3); 495.		
		Pacheco M, et al; "Aminoalkylindoles: Actions On Specific G-Protein-Linked Receptors"; J. Pharmacol. Exp. Ther.; vol. 257, no. 1, pp. 170-183 and 172 Table (1991).		
		1 *2* Palmer et al; "Natural and Synthetic Endocannabinoids and Their Structure-Activity Relationships"; Current Pharmaceutical Design; 6; 1381-1397; (2000)		
		1 Pertwee et al; "Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine"; Br. J. Pharmacol.; 105(4); 980-984 (1992). (abstract only)		
		*1* Pinto et al; Cannabinoid Receptor Binding and Agonist Activity of Amides and Esters of Arachidonic Acid; Mol. Pharmacol.; 1994; 46(3); 516-522. (abstract only)		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	1 *2* Pommery F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F.; "Roles of mu, delta and kappa opiod receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; J. Pharmacol. Exp. Ther.; 230(2); 341-348; (1994). (abstract only)			
	Quere, L., Boigegrain, R., Jeanjean, F., Gully, D., Evrard, G., Durant, F.; "Structural requirements of non-peptide neurotensin receptor antagonists"; J. Chem Soc., Perkin Trans. 2, (1996); 2639-2646.			
	1 Razdan et al; "Pharmacological and Behavioral Evaluation of Alkylated Anandamide Analogs"; Life Sci.; 1995; 56(23-24); 2041-2048 (abstract only)			
	2 Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414. (abstract only)			
	1 *2* Serdarevich B., Caroll K.K., "Synthesis and characterization of 1- and 2-monoglycerides of anteiso fatty acids"; J. Lipid Res.; 7; 277-284; (1966)			
	2 Shen M. Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.			
	1 Sheskin, T. et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667			
	2 Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. (abstract only)			
	2 Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172 (abstract only)			
	Tetko, I. V. et al; "Volume Learning Algoritm Artificial Neural Networks For 3D QSAR Studies"; J. Med. Chem.; vol. 44, no. 15 (2001) pp. 2411-2420, 2413, 2414 Table 1.			
2 Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534 (abstract only)				
	2 Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R.; "Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase"; J. Neurochem.; 61(1) 352-355; (1993) (abstract only)			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
DWI	*2* Wagner SA, Varga K, Jarai Z, Kunos G; "Mesenteric Vasodilation Mediated by Endothelia Anandamide Receptors"; Hypertension (1999) 33:429-434.		
Examiner Alton Kryor	Date Considered 4/1/05		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



MAY 26 2004

RECEIVED

**INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION**

May 18, 2004

Application No.

09/328,742

Inventor

Alexandros Makriyannis et al

Title

Inhibitors Of The Anandamide Transporter As Analgesic Agents

Filing Date

June 6, 1999

Group Art Unit

1616

Docket No.

UCONAP/141/US

UNITED STATES PATENT DOCUMENTS


Examiner Initial	Document No.	Date	Name	Class
AN	09/600786		to Makriyannis et al (US National phase of Int'l App. No. PCT/US99/28136, published as WO 00/32200)	
	09/701989		to Makriyannis et al (US National phase of Int'l App. No. PCT/US99/12900, published as WO 00/64389)	
	3465024		to Brownstein et al	
	3577458		to Brownstein et al	
	4812457		to Narumiya	
	5576436		to McCabe et al.	
	5618955		to Mechoulam et al	
	5688825		to Makriyannis et al	
	5804601		to Kato et al	
	5925628		to Lee et al	
	6391909		to Makriyannis et al	
AW	6579900		to Makriyannis et al	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Date	Country	Name	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


Examiner Initial	
AW	Barnett-Norris et al; "exploration of biologically relevant conformations of anandamide, . . ."; J. Med. Chem.; vol. 41; 4861-4872; 1998



MAY 26 2004

TECH CENTER 16000000

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al
		Title Inhibitors Of Th Anandamide Transp r t r As Analg sic Agents	
		Filing Date June 6, 1999	Docket No. UCONAP/141/US
<i>AWP</i>	Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . ."; Prostaglandins, leukotrienes and essential fatty acids; 59(2); 111-118; (1998). (abstract only)		
	*** BioWorld Today, Volume 8(162), August 21, 1997		
	Cherest M., Luscindi X.; "The action of acetyl chloride and of acetic anhydride on the lithium nitronate salt of 2-phenylnitroethane . . ."; Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract		
	Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloiride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989		
	*** Compton D.R. et al; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992		
	*** D'Amour F.E., Smith D.L.; J. Pharmacol. Exp. Ther.; 72; 74-79; 1941		
	Demuyneck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract		
	Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRCA9; ISSN:0006-291X; XP002040933		
	Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993		
	Fride & Mechoulam; "Pharmacological activity of the cannabinoid receptor agonist; . . ."; European Journal of Pharmacology, vol. 231; 313-314; 1993		
	Hillard C. J., Edgemon, W. S., Jarrahan W., Campbell, W. B; "Accumulation of N-Arachidonylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion"; Journal of Neurochemistry; 69; 631-638 (1997)		
	Horrevoets A.J.G et al; "Inactivation of escherichia coli outer membrane phospholipase A by the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 247-253; 1991		
<i>AWP</i>	Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989		



MAY 26 2004

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors Of The Anandamide Transporter As Analgesic Agents		
	Filing Date June 6, 1999	Group Art Unit 1616	Docket No. UCONAP/141/US
<i>[Signature]</i>	Koutek B. et al; "Inhibitors of arachidonyl ethanolamide hydrolysis"; J. Biol. Chem.; 269(37); 22937-40; 1994; CODEN: JBCHA3; ISSN: 0021-9258; XP002040931		
<i>[Signature]</i>	Neunhoeffer O., Gottschlich R.; "Acylating activity of O-acylated hydroxylamine derivatives"; Justus Liebig's Ann. Chem.; 736; 100-109; 1970; in German with English abstract		
	*** Pertwee et al; Br. J. Pharmacol.; 105; 980 1992		
<i>[Signature]</i>	Smith P.B. et al; "The pharmacological activity of anandamide, a putative endogenous cannabinoid, . . ." journal of pharmacology and experimental therapeutics; vol. 270(1):219-227; 1994 (abstract only, attached to Twitchell abstract)		
<i>[Signature]</i>	Twitchell, W. et al; "Cannabinoids inhibit N- and P/Q type calcium channels in cultured rat hippocampal neurons"; Journal of Neurophysiology; 78(1); 43-50; 1997 (database CAPLUS on STN (Columbus, OH, USA) DN 127:199945 (abstract only)		
Examiner	Date Considered		
<i>Alton Pryor</i>	<i>4/11/05</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

G:\AYR saved docs\Filing Docs\Uconap\conap141us\conap141us 5-04 ids.doc